Grace Colón participated in a three-part virtual workshop: Innovation in Drug Research and Development for Prevalent Chronic Diseases. This virtual public workshop provided a venue for stakeholders to examine bottlenecks to innovation in drug research and development (R&D) for prevalent chronic diseases and highlight opportunities...
InCarda Therapeutics CEO Grace Colón was interviewed for this brief and informative piece on Atrial Fibrillation, The Hidden Heart Problem That's Claiming Men's Lives Now by Julie Stewart in the February 2021 edition of Men’s Health. Key points: “There’s a U-shaped curve with AFib—people who don’t exercise...
Ongoing Trial to Evaluate Optimal Dose Selected from Dose-Ranging Stage of the INSTANT Study for Rapid Conversion of Atrial Fibrillation to Normal Sinus Rhythm SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular...
Our CEO Grace Colón participated in the panel "Cardiovascular and Nephrology: a Renewed Interest" at Biotech Showcase 2021 on January 11, 2021. More information below: Drug development in nephrology and cardiovascular specialties have had a revival of venture investments in recent years, after facing headwinds regarding...
Grace Colón joins the First Rounders Podcast (aired on 1/2/21). The conversation covers growing up in San Juan; her love musical theater; and how grad school at MIT guided her toward a career in entrepreneurship. https://play.acast.com/s/naturebiotechnologypodcast/gracecolon...
Grace Colón and Jeff Ho join a FIRESIDE chat with Umer Raffat & Michael DiFiore on Dec 2, 2020. Grace and Jeff share an overview of how InCarda Therapeutics, Inc will be changing the lives of patients with AFIB. Grace Colón and Jeff Ho join a...
On Friday, November 13 at 9:00am CT/10:00am ET, Dr. Harry Crijns, Clinical Electrophysiologist from Maastricht University Medical Center in the Netherlands, will present data from the open-label, dose-escalation Part A portion of InCarda’s multinational INSTANT Phase 2 clinical trial of InRhythm™ (flecainide for inhalation) in...
Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Provides Roadmap for Start of Pivotal Phase 3 in Medically Supervised Setting in 2021 San Francisco, CA...
InCarda Therapeutics and our President & CEO Grace Colón were featured in a recent post on Endpoints News. The post highlights InCarda's Raise of $30 Million Through First Close of Series C Equity Financing. More information below: “This is especially exciting at a time when more...
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for Presentation at American Heart Association Scientific Sessions 2020; Pivotal Phase 3 Study Planned for Initiation in H1 2021 SAN FRANCISCO, Oct. 21,...